Gene Therapy in Oncology

Talmadge, James E.; Cowan, Kenneth H.

doi:10.1016/b978-0-323-47674-4.00029-3

Cited by 3 publications

(3 citation statements)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SiRNA, which is a type of RNA interference (RNAi), is also used in this method. Some of siRNA targets in breast cancer treatment include: Cell cycle regulators, proto‐oncogenes, signalling proteins, proteins involved in drug resistance, and angiogenic factors 15,96,97 …”

Section: Gene Therapy Strategies For Bc Treatmentmentioning

confidence: 99%

“…Talimogene laherparepvec (Imlygic, BioVec, a subsidiary of Amgen) approved in December 2015 by the EU, is a Herpesvirus vector for the treatment of regionally or distantly metastatic melanoma. In May 2016, a retroviral vector, Strimvelis (GlaxoSmithKline) was approved by the EU for the treatment of severe combined immunodeficiency (SCID) and adenosine deaminase (ADA) deficiency 97 . In October 2017, for the treatment of patients with relapsed or refractory large B cell lymphoma, Axicabtagene ciloleucel (Yescarta, Kite, a subsidiary of Gilead Sciences, Inc) was approved by the FDA (Food and drug administration).…”

Section: Clinical Trials In Gene Therapymentioning

confidence: 99%

See 1 more Smart Citation

Gene therapy: A promising approach for breast cancer treatment

Dastjerd

Valibeik

Monfared

et al. 2021

Cell Biochemistry & Function

View full text Add to dashboard Cite

Breast cancer (BC) is the most prevalent malignancy and the second leading cause of death among women worldwide that is caused by numerous genetic and environmental factors. Hence, effective treatment for this type of cancer requires new therapeutic approaches. The traditional methods for treating this cancer have side effects, therefore so much research have been performed in last decade to find new methods to alleviate these problems. The study of the molecular basis of breast cancer has led to the introduction of gene therapy as an effective therapeutic approach for this cancer. Gene therapy involves sending genetic material through a vector into target cells, which is followed by a correction, addition, or suppression of the gene. In this technique, it is necessary to target tumour cells without affecting normal cells. In addition, clinical trial studies have shown that this approach is less toxic than traditional therapies. This study will review various aspects of breast cancer, gene therapy strategies, limitations, challenges and recent studies in this area.

show abstract

Section: Gene Therapy Strategies For Bc Treatmentmentioning

confidence: 99%

Section: Clinical Trials In Gene Therapymentioning

confidence: 99%

Gene therapy: A promising approach for breast cancer treatment

Dastjerd

Valibeik

Monfared

et al. 2021

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Adenoviral vectors are non-enveloped double-stranded DNA vectors with a capacity of packing around 35kb (Talmadge and Cowan, 2020). The AdV vectors may be divided into two regions: early (E) -comprehending E1, E2, E3, and E4 regions, and late (L) -L1, L2, L3, L4, and L5 regions, each one named according to the time of their expression during the virus replication.…”

Section: Adenoviral Vectorsmentioning

confidence: 99%

Protection is not always a good thing: The immune system’s impact on gene therapy

et al. 2022

View full text Add to dashboard Cite

There are many clinical trials underway for the development of gene therapies, and some have resulted in gene therapy products being commercially approved already. Significant progress was made to develop safer and more effective strategies to deliver and regulate genetic products. An unsolved aspect is the immune system, which can affect the efficiency of gene therapy in different ways. Here we present an overview of approved gene therapy products and the immune response elicited by gene delivery systems. These include responses against the vector or its content after delivery and against the product of the corrected gene. Strategies to overcome the hurdles include hiding the vector or/and the transgene product from the immune system and hiding the immune system from the vector/transgene product. Combining different strategies, such as patient screening and intelligent vector design, gene therapy is set to make a difference in the life of patients with severe genetic diseases.

show abstract